Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

IO Biotech, Inc.

$0.05

+0.02 (+68.42%)

D 36Pipeline Score Fair Value Biotech · Clinical
Market Cap
3.45 M
EPS
-1.34
P/E Ratio
-
Value Trade
30.37 M
SEC Financials
Q3 2025

  • Dilution Risk

    95%

  • R&D Expenses

    13.74 M

  • Total Assets

    39.96 M

  • Total Liabilities

    39.05 M

  • Equity

    911.00 K

  • D/E Ratio

    12,345

-75.56 %
Week
-84.64 %
1 Month
-92.07 %
3 Month
-90.46 %
6 Month
-99.7 %
5 Year
-99.7 %
All Time
Cash Data
Critical

  • Cash Position

    30.66 M

  • Monthly Burn

    6.45 M

  • Runway

    0 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    Nov 14, 2025
Overview
Volume
481.59 M
52 Week Range
0.03 - 2.79
% held by Insiders
16.12 %
% held by Institutions
40.08 %
Enterprise Value
-9.09 M
Total Shares
72.06 M
Short %
15.48 %
Float Shares
13.91 M
Company Description
HQ: OLE MAALOES VEH 3, COPENHAGEN,...
Founded:2014
Employees:78
https://www.iobiotech.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D36
Pipeline Score
$8M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
2.2x
rNPV / MCap
Top 48%
Micro Cap
(rank 475 of 911)
Percentile Rank
IO Biotech, Inc. faces pipeline headwinds (36/100), with $2.4B risk-adjusted pipeline value, led by IO102 in NSCLC (Phase 1), across $61B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
IO102/IO103
Small molecule		MelanomaPhase 2NCT0591224443% $1.1B ACTIVE NOT_RECRUITING 43 - -Jun 9, 2027 -LOW
May 24, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
IO102-IO103
Breakthrough
metastatic melanoma
Phase 1/2
2025-12-15

median progression free survival: 25.5 months; median overall survival: 60 months; median duration of response: more than 53 months

Read More

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

Read More
IO102-IO103
Breakthrough
metastatic melanoma
Phase 1/2
2025-12-15

median progression free survival: 25.5 months; median overall survival: 60 months; median duration of response: more than 53 months

Read More

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

Read More
IO102-IO103
Breakthrough
metastatic melanoma
Phase 1/2
2025-12-15

median progression free survival: 25.5 months; median overall survival: 60 months; median duration of response: more than 53 months

Read More

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in IOBT
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
IOBT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How IOBT ranks across every disease it competes in
Competitive Position is a premium feature
See how IOBT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial